<DOC>
	<DOCNO>NCT00004430</DOCNO>
	<brief_summary>OBJECTIVES : I . Demonstrate safety efficacy dihematoporphyrin derivative ( DHP ) laser photodynamic therapy ( PDT ) patient corneal neovascularization . II . Document histopathologic mechanism action select patient undergo penetrate keratoplasty follow PDT therapy corneal neovascularization . III . Facilitate FDA product approval DHP photosensitizing agent laser treatment patient . IV . Explore use photosensitizer ocular cutaneous basal cell squamous cell carcinoma .</brief_summary>
	<brief_title>Randomized Study Photodynamic Therapy Using Dihematoporphyrin Patients With Corneal Neovascularization</brief_title>
	<detailed_description>PROTOCOL OUTLINE : This randomize , placebo control study . Patients randomize 1 3 treatment arm : Arm I : Patients receive topical dihematoporphyrin derivative ( DHP ) every 3 hour day -3 -2 . Patients undergo laser surgery day 0 . After photodynamic ( PDT ) therapy , patient receive topical prednisolone phosphate four time day 90 day . Ninety day follow PDT , patient may undergo corneal transplantation . Arm II : Patients receive placebo topical gel undergo sham laser surgery follow arm I schedule , receive topical prednisolone phosphate four time day 90 day . Patients may cross arm I disease progression observe . Arm III : Patients receive compressed 1 day schedule DHP 5 dos morning undergo laser surgery evening . Patients assess day 1 , 7 , 30 , 90 PDT therapy . Completion date provide represent completion date grant per OOPD record</detailed_description>
	<mesh_term>Neovascularization , Pathologic</mesh_term>
	<mesh_term>Corneal Neovascularization</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<criteria>Histologically proven corneal neovascularization ( CNV ) : Must least 1 quadrant significant CNV , due bacterial , viral , parasitic , fungal keratitis ; alkaline acid hydrocarbon chemical burn ; ocular trauma injury ; severe ocular surface disease ; previous surgery complication corneal allograft rejection eligible No concurrent systemic steroids No concurrent immunosuppressive therapy Not pregnant nursing ; Negative pregnancy test ; Fertile patient must use effective contraception ; HIV negative ; No rheumatoid arthritis ; No congenital corneal scar ; No active ocular infection inflammation ; No active systemic collagen vascular disease ; No uncontrolled glaucoma ; No history porphyrin allergy ; Visual acuity 20/400 good contralateral eye</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2000</verification_date>
	<keyword>cardiovascular respiratory disease</keyword>
	<keyword>corneal neovascularization</keyword>
	<keyword>rare disease</keyword>
</DOC>